Navigation Links
Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis
Date:10/27/2008

e soluble and membrane-bound forms of TNF- alpha.

Centocor discovered golimumab and has exclusive marketing rights to the product in the United States. Pending regulatory approval, Schering-Plough will assume exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan where golimumab will be co-marketed by Mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where golimumab will be exclusively marketed by Janssen-Cilag; and China where golimumab will be exclusively marketed by Xian-Janssen.

About Centocor

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.

The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients suffering from debilitating immune disorders. Centocor is a wholly-owned subsidiary of Johnson & Johnson.

CENTOCOR DISCLOSURE NOTICE: This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Centocor's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
2. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
4. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
9. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
10. Phase III Trial Finds Pharmaxis Bronchitol Effective
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Bi-Biomics today announced a discovery ... additive. The improvement in histological quality provided the ... in all daughter cells. , After processing with ... analyzed at 1000-1600x using light microscopy. Phylogenetic ... all daughter cells displayed predominant binary features --- ...
(Date:3/5/2015)... and TORONTO , March 5, ... a clinical-stage company developing new therapeutics and molecular diagnostics ... that William G. Rice , Ph.D., Chairman, President ... 27th Annual ROTH Conference on Tuesday, March 10 th ... Carlton, Laguna Niguel, CA. Dr. ...
(Date:3/5/2015)... DUBLIN , Mar. 05, 2015 Research and ... addition of the "Mature Biotech Outlook 2015: New ... to their offering. All biotech companies ... Celgene (CELG), in past year, have given a positive ... These companies have been able to select therapy/niche indication ...
(Date:3/5/2015)... e2b teknologies , a premier Sage ... Ohio, today announced a leading independent multi-specialty physician group ... to the latest version of Sage 100 ERP ... its kind in the region, the organization has an ... efficiency and data accessibility are paramount to their ongoing ...
Breaking Biology Technology:Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2
... NEW YORK, June 18 In designing and conducting ... while preventing program "drift," according to Matthew Lehman, chief ... remarks at a recent seminar for biotechnology companies. ... for Success: Balancing FDA Expectations and Operational Reality," at ...
... Germany, June 18 2009 is the year of the ... cytometer - the ICP 11. , ... State Vineyard Castle Wackerbarth near Dresden. For the festive,ceremony, CEO ... society. , In 1968, the fluorescence ...
... event and prepare for it, according to new research ... that appeared today in Nature , Prof. Yitzhak ... Orna Dahan of the Institute,s Molecular Genetics Department, together ... Aviv University, examined microorganisms living in environments that change ...
Cached Biology Technology:Matthew Lehman of SPRI Clinical Trials Speaks On Designing Trials For Success At The Trout Group Investor Relations Seminar 2A Worldwide Milestone in Cell Analysis - 40 Years of Flow Cytometry 2Israeli scientists show bacteria can plan ahead 2Israeli scientists show bacteria can plan ahead 3
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/5/2015)... 2015   Epic Sciences , a precision diagnostics company ... Murali Prahalad , Ph.D., president and CEO, is scheduled ... (PMWC) 2015: Silicon Valley, which is taking place at the ... on January 26-28, 2015. Dr. Prahalad ... Biomarkers." Last year, Epic Sciences was a finalist in the ...
(Date:2/5/2015)... 2015 Research and Markets ( ... "Global Biometrics Market (2014-2020): Market Forecast By ... report to their offering. , ... is anticipated to overtake North ... government spending towards IT security, government biometric based ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... -- A new study by Georgetown University Medical Center researchers ... to stop cancer cell growth. The findings, published online ... which is mutated in a majority of families who have ... I. Yarden, PhD, assistant professor in the Department of Human ...
... A new model of the how the protein coat ... access journal BMC Biophysics , shows that ... capsid production (hierarchical assembly) can be more efficient than ... capsid enveloping a virus is essential for protection and ...
... genomic data into meaningful information about the cell is ... human biology and medicine. Researchers at the University of ... proposed a new method that creates a computational model ... protein interactions, discovering how genes and proteins connect to ...
Cached Biology News:Study uncovers mechanism used by BRCA1 to suppress tumors 2Do-it-yourself viruses: How viruses self assemble 2Toward a new model of the cell 2Toward a new model of the cell 3
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
... Klein Taq is a derivative of Taq ... truncated Thermus aquaticus DNA polymerase. Expressed from ... initiates at Met236, bypassing the 5'-3' exonuclease ... enzyme reveals a highly active and even ...
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
96 Well Base Plate...
Biology Products: